Related Experiment Videos
Etoposide and cisplatinum in resistant lymphomas
N Tubiana1, C Lejeune, N Horchowski
1Institut J. Paoli-I. Calmettes, Marseille, France.
Cancer Chemotherapy and Pharmacology
|January 1, 1987
Summary
This study combined etoposide and cisplatinum chemotherapy for refractory lymphomas. The novel combination showed promising response rates in heavily pretreated patients, with acceptable side effects.
Area of Science:
- Oncology
- Pharmacology
Background:
- Refractory lymphomas present a significant challenge in clinical practice.
- Etoposide and cisplatinum are established chemotherapeutic agents with distinct mechanisms of action.
Purpose of the Study:
- To evaluate the efficacy and safety of combining etoposide and cisplatinum for treating refractory lymphomas.
- To explore the synergistic potential of etoposide and cisplatinum in this patient population.
Main Methods:
- A cohort of 22 extensively pretreated patients with refractory lymphomas received combination therapy.
- Cisplatinum was administered as a continuous infusion (15 mg/m²/d for 5 days).
- Etoposide was given as a push injection (100 mg/m²/d on days 1 and 2).
Main Results:
- The combination therapy achieved good responses in 18 out of 22 patients.
- This included 15 partial remissions and 3 complete remissions.
- Reported side effects were deemed acceptable.
Conclusions:
- The combination of etoposide and cisplatinum demonstrates significant efficacy in refractory lymphomas.
- This regimen offers a viable treatment option for patients with limited prior treatment successes.
- Further investigation into this synergistic combination is warranted.